# Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.

> **NCT02206308** · PHASE1 · COMPLETED · sponsor: **Sinocelltech Ltd.** · enrollment: 15 (actual)

## Conditions studied

- B-cell Non Hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** Chimeric anti-CD20 monoclonal antibody

## Key facts

- **NCT ID:** NCT02206308
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2014-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02206308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02206308, "Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02206308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*